-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Vedolizumab for the treatment of inflammatory bowel diseases
Reena Khanna & Brian G Feagan
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
How can we manage resistance to antiangiogenic drugs?
Dai Chu Luu, Joseph Chao
Editorial: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Article: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
Ariane Klein, Gerd Horneff
Review: Clinical Trail Outcomes: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation